Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 2Breast 2Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 69Triple Negative Breast Neoplasms 32Ovarian Neoplasms 21Neoplasm Metastasis 10Prostatic Neoplasms 8Pancreatic Neoplasms 7Fanconi Anemia, Complementation Group D1 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Recurrence 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Inflammatory Breast Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Ovarian 1

Interventions

pembrolizumab 14Gemcitabine 8Docetaxel 7Nivolumab 6durvalumab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5atezolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4sargramostim 3aldesleukin 3Specimen Handling 3Radiotherapy 3Paclitaxel 3Ipilimumab 3Fulvestrant 3Cisplatin 3Carboplatin 3venetoclax 2temsirolimus 2talazoparib 2spartalizumab 2olaparib 2liposomal doxorubicin 2fludarabine phosphate 2cabozantinib 2budigalimab 2avelumab 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × olaparib × Breast × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02734004 2026-04-20

MEDIOLA

AstraZeneca

Phase 1/2 Active not recruiting
264 enrolled 32 charts
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡